Ascendis Pharma director reports initial holdings

Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. He directly holds 384,933 ordinary shares and indirectly holds 68,470 ordinary shares through Cadenza Partners.

The filing lists several fully vested, currently exercisable warrant series over ordinary shares with exercise prices ranging from 37.18 to 176.28 and expirations from December 2027 through December 2031. It also discloses three restricted stock unit awards over ordinary shares (delivered as ADSs) covering 15,825, 23,834 and 28,945 underlying shares, which vest beginning on March 1, 2027.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider MIKKELSEN JAN MOLLER

Role Director

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Warrants	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Restricted Stock Units	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 690,611 contracts (Direct); Restricted Stock Units — 68,604 contracts (Direct); Ordinary Shares — 384,933 shares (Direct); Ordinary Shares — 68,470 shares (Indirect, By Cadenza Partners)

Footnotes (6)

F1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
F2. The warrants are fully vested and currently exercisable.
F3. The restricted stock units vest on March 1, 2027 and have no expiration date.
F4. Each restricted stock unit represents a contingent right to receive one ADS.
F5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
F6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascendis Pharma (ASND) disclose in Jan Moller Mikkelsen’s Form 3?

Ascendis Pharma reported director Jan Moller Mikkelsen’s initial ownership, including ordinary shares, warrants and restricted stock units. The filing establishes his baseline equity exposure as a board member, combining direct and indirect holdings plus multiple derivative awards over Ascendis Pharma ordinary shares and ADSs.

How many Ascendis Pharma ordinary shares does Jan Moller Mikkelsen hold?

The director directly holds 384,933 Ascendis Pharma ordinary shares and indirectly holds 68,470 additional ordinary shares through Cadenza Partners. This combination reflects both his personal stake and an associated entity position, as reported in the initial Form 3 ownership statement for ASND.

What warrant positions over Ascendis Pharma (ASND) shares are reported?

The Form 3 lists fully vested, currently exercisable warrants over several blocks of Ascendis Pharma ordinary shares, with exercise prices from $37.18 to $176.28 and expirations between December 2027 and December 2031, giving the director long-dated option-like exposure to ASND equity.

What restricted stock units does Jan Moller Mikkelsen hold in Ascendis Pharma?

The filing shows three restricted stock unit grants over 15,825, 23,834 and 28,945 underlying Ascendis Pharma ordinary shares. These RSUs vest beginning March 1, 2027, in annual installments, and each unit represents a contingent right to receive one American Depositary Share.

How are American Depositary Shares (ADS) described in the Ascendis Pharma Form 3?

The Form 3 explains that Ascendis Pharma American Depositary Shares represent the company’s ordinary shares on a one-for-one basis. Each ADS equals one ordinary share, and the restricted stock units provide a contingent right to receive one ADS when vesting conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 06:05 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MIKKELSEN JAN MOLLER

(Last)

(First)

(Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

DK-2900

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares⁽¹⁾	384,933	D
Ordinary Shares⁽¹⁾	68,470	I	By Cadenza Partners

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants	⁽²⁾	12/12/2027	Ordinary Shares	200,000	$37.18	D
Warrants	⁽²⁾	12/11/2028	Ordinary Shares	200,000	$62.17	D
Warrants	⁽²⁾	12/10/2029	Ordinary Shares	120,000	$108	D
Warrants	⁽²⁾	12/20/2030	Ordinary Shares	101,145	$176.28	D
Warrants	⁽²⁾	12/09/2031	Ordinary Shares	69,466	$139.65	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Ordinary Shares	15,825	⁽⁴⁾	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Ordinary Shares	23,834	⁽⁴⁾	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Ordinary Shares	28,945	⁽⁴⁾	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants are fully vested and currently exercisable.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Jan Mikkelsen	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR